PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM
Abstract
Authors
GH Mickisch B Escudier M Gore S Walzer MJ Nuijten